Acute respiratory distress syndrome (ARDS) is a severe lung disease associated with high mortality despite recent advances in management. Significant advances in extracorporeal membrane oxygenation (ECMO) devices and management allow short-term support for patients with acute reversible respiratory failure and can serve as a bridge to transplantation in patients with irreversible respiratory failure. When ARDS does not respond to conventional treatment, ECMO and the interventional lung assist membrane (iLA) are the most widely used complementary treatment options. Here, we report a clinical case of an adult patient who required prolonged duration venovenous (VV)-ECMO for severe ARDS resulting in improvement while waiting for lung transplantation.
The acute respiratory distress syndrome (ARDS) is asevere lung diseaseassociated mortality rate despite recent advances in the management of patients. [1] [2] [3] In CESAR trial, ECMO treatment in severe ARDS patient showed a significant improvement in survival at 6 month. [4] Significant advances in ECMO device and management allow short-term support for patients with acute reversible respiratory failure, and bridge to transplantation in patients with irreversible respiratory failure. [5] When ARDS does not respond to conventional treatment, ECMO and the interventional lung assist membrane (iLA) are the devices most widely developed as complementary treatment options. However, there are no established national guideline when to consider futility or lung transplantation in adult patients requiring ECMO for acute respiratory failure. [6] We report the clinical case of an adult patient who required prolonged duration veno-venous (VV)-ECMO for severe ARDS resulted in improvement during waiting lung transplantation eventually.
Case Report
A 27-year-old healthy man presented with abdominal pain for 5 days. He had a treatment history of pulmonary tuberculosis many years ago. He complained headache, myalgia, and fever up to 38.5℃. Initially, he was admitted to general ward of a tertiary other hospital and performed the abdominal computed tomography (CT). The intestinal tuberculosis or Crohn's disease were suspected in radiologic finding. (His final diagnosis was Crohn's disease) So the patient took the medicine for intestinal tuberculosis (isoniazid, rifampin, etambutol, pyrazinamide). But, his symptom was not improved at all. To find the cause of fever, the attending physicians performed various test including blood culture, cerebrospinal fluid tapping, autoimmune marker. But there were not meaningful results. After 6 days in the hospital, pleural effusion was seen in the chest X-ray ( (Table 1) . He was successfully weaned from VV-ECMO and was decannulated (total VV-ECMO duration:
85 days). His clinical course is summarized in Fig. 2 . His ECMO course was complicated by multiple episodes of Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia in endotracheal aspiration and blood culture, which were treated by antibiotics for a long time (Fig. 3) , and overt bleeding requiring hemoclip and fibrin glue at percutaneous endoscopic gastrostomy site.
While maintain the ECMO, the patient did not use the anticoagulation agent because of consistently thrombocytopenia (platelet < 50,000/ul). The patient's lung function continued to A B C Fig. 2 improve, and he was successfully weaned from mechanical ventilation (cumulative ventilator duration: 129 days). He was transferred to the general ward for inpatient rehabilitation. 34 days after discharge from ICU, the patient was discharged home without supplemental oxygen. On follow-up, chest X-ray showed low lung volumes with diffuse interstitial and patchy parenchymal opacities, suggesting sequelae of ARDS (Fig. 1C) .
Discussion
In many randomized trial, lung protective strategy including ventilation of lower tidal volume [1] and prone position [7] showed survival benefit in the treatment of ARDS. Recently, ECMO has been widely used for patients with respiratory failure to assist adequate gas exchange in severely damaged lungs, thus allowing the decrease of adjusted tidal volume and preventing the ventilator-induced lung injury. And some papers in support of this were also published. Lewandowski et al. [8] , in the nonrandomized study, the survival rates of patients treated with ECMO is to demonstrate that it was significantly higher than the control (55% versus 89%, p < 0.0001). Hemmila et al. [9] announced the experiments with adult patients with ARDS of 255 treated with ECMO. This study showed the survival rate of 52% of sub-group of patients very serious, patients with ARDS very strict included. The recently published CESAR study, for the treatment of severe respiratory failure, compares ECMO with the conventional method of ventilation in adults. [10] In the study, 180 patients were randomized to two groups of interventional group (ECMO support) and control group (conventional treatment). The interventional group presented higher survival rate (63% versus 47%) to improving the quality of life in the follow-up of 6 months. [4] However, the above studies were conducted by medical staff with highly experienced ECMO. So, it is necessary to pay attention to interpretation. It is the strongest argument for ECMO is not well established increase in survival associated with this technology. In spite of various studies showing the capacity of ECMO as a gas exchange support system [8, [11] [12] [13] it is difficult to extend ECMO as a conventional treatment in adults with ARDS for various reasons: [14] the lack of scientific evidence supporting the use of ECMO in adult ARDS patients, bleeding risk by the anticoagulation with heparin, [8, 11, 13, 15, 16] and the elevated economic costs along with the need for highly qualified staff. The use of iLA (Novalung Although both iLA and ECMO can be used in patients with respi-ratory distress, iLA is less invasive and shows less complications.
However, iLA is not suitable for patients with hypoxemia, such a case consider ECMO. The indication for ECMO must be carefully evaluated on a case-by-case basis and be considered as a salvage treatment or complementary treatment option in refractory ARDS. The current paradigm of consideration of lung transplantation because of irreversible lung failure at 2-4 weeks' duration of VV-ECMO and questions the specific time at which /we should consider that there is no likelihood of lung recovery. [6] In spite of various treatments, the patient of ARDS becomes worsening, we can consider lung transplantation. Nowadays, ECMO is not only as a gas exchanger, as well as a bridge to lung transplantation.
Many physicians will focus on ECMO. There has been increasing use of ECMO as a bridge to lung transplantation; however, chronic lung disease, particularly pulmonary fibrosis, is the most common indication not ARDS. The role of ECMO as a bridge to lung transplantation has recently been suggested due to advancements in ECMO systems. [17] Recent studies have reported ECMO support for 107 and 110 days. [18] [19] [20] In the other case, they report the clinical course of an adult patient who had been evaluated for bridge to lung transplantation and required long-term period VV-ECMO for severe ARDS with the recovery of lung eventually.
It demonstrates unexpected lung recovery as the patient was undergoing preparation for possible lung transplantation. The lung may have unexpected regenerative capacity with native lung recovery after prolonged mechanical support, similar to acute kidney injury and renal recovery. [6] In our case, in consideration of lung transplantation, the patients were transferred to our hospital.
Although tidal volume was low, chest X-ray was improved day by day. Because the patient was young and no chronic lung disease, we were waiting for natural recovery.
Lung transplantation in the refractory ARDS patients may be considered as treatment option if the patient was young and previous healthy. If the patient does not have chronic lung disease and can expect reversibility, we recommend that the patient can expect the recovery of lung function applying lung protective strategy and long-run ECMO.
